• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

沙特阿拉伯吉赞地区原发性肝细胞癌患者的乙肝和丁肝标志物

Hepatitis B and delta markers in primary hepatocellular carcinoma patients in the Gizan area of Saudi Arabia.

作者信息

Arya S C, Ashraf S J, Parande C M, Tobeiqi M S, Ageel A R

机构信息

Department of Medicine, King Fahad Central Hospital, Gizan, Saudi Arabia.

出版信息

APMIS Suppl. 1988;3:30-4.

PMID:2846019
Abstract

Hepatitis B virus (HBV) has been hyperendemic in the Gizan area of Saudi Arabia, located 17 degrees N 43 degrees E, with 20% male and 9% female HBsAg carriers among the native population. Among HBsAg carriers, 8% have been positive for anti-delta antibody while intravenous drug abuse and alcohol have been unknown. Monthly hospitalisation of primary hepatocellular carcinoma (PHC) patients from a catchment population of 500,000 approximates 2-3. HBV markers were tested in 30 PHC cases and compared with 326 otherwise healthy natives. Both HBsAg and total HBV exposure were higher among PHC (p less than 0.001), with no difference between sexes. Anti-delta antibody was demonstrable in 5 of 30 HBsAg-positive PHC with similar distribution among PHC, healthy carriers and those with chronic hepatic disorders. Serum aliquots from 3 hitherto HBV-negative PHC cases are to be tested for HBV-DNA along with immunohistochemical staining on biopsy material. Pending reduction in PHC incidence decades later, subsequent to initiation of HBV immunization, regular examination of HBsAg carriers and established cirrhotics for alphafetoprotein level and ultrasonic hepatic lesions would constitute important interim measures both towards early detection of, and an effective chemotherapy/surgery for, hepatic malignancy.

摘要

乙型肝炎病毒(HBV)在沙特阿拉伯吉赞地区(北纬17度,东经43度)呈高度地方性流行,当地原住民中HBsAg携带者男性占20%,女性占9%。在HBsAg携带者中,8%的抗δ抗体呈阳性,而静脉吸毒和酗酒情况不明。在一个50万人口的集水区,原发性肝细胞癌(PHC)患者的月住院人数约为2至3人。对30例PHC病例进行了HBV标志物检测,并与326名其他方面健康的当地人进行了比较。PHC患者中HBsAg和总的HBV暴露水平均较高(p<0.001),男女之间无差异。在30例HBsAg阳性的PHC患者中,有5例可检测到抗δ抗体,在PHC患者、健康携带者和慢性肝病患者中的分布相似。将对3例迄今HBV阴性的PHC病例的血清样本进行HBV-DNA检测,并对活检材料进行免疫组织化学染色。在开始HBV免疫接种几十年后,在PHC发病率降低之前,定期检查HBsAg携带者和已确诊的肝硬化患者的甲胎蛋白水平及肝脏超声病变,将是早期发现肝恶性肿瘤并对其进行有效化疗/手术的重要临时措施。

相似文献

1
Hepatitis B and delta markers in primary hepatocellular carcinoma patients in the Gizan area of Saudi Arabia.沙特阿拉伯吉赞地区原发性肝细胞癌患者的乙肝和丁肝标志物
APMIS Suppl. 1988;3:30-4.
2
Serological profiles for HBV, HDV, HIV-1 and HTLV-1 in Saudi patients with a malignancy.沙特恶性肿瘤患者的乙肝病毒、丁型肝炎病毒、人类免疫缺陷病毒1型和人类嗜T淋巴细胞病毒1型血清学特征。
J Commun Dis. 1991 Dec;23(4):270-5.
3
Hepatitis B virus e antigen and primary hepatocellular carcinoma.乙肝病毒e抗原与原发性肝细胞癌
Anticancer Res. 1991 Nov-Dec;11(6):2063-5.
4
Seroprevalence of hepatitis B and C viral markers in patients with primary hepatocellular carcinoma in Singapore.新加坡原发性肝细胞癌患者中乙型和丙型肝炎病毒标志物的血清流行率。
Singapore Med J. 1996 Oct;37(5):492-6.
5
High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia.蒙古慢性肝病患者中乙型、丙型和丁型肝炎病毒双重或三重感染的高流行率。
J Med Virol. 2005 Dec;77(4):491-9. doi: 10.1002/jmv.20482.
6
A profile of primary hepatocellular carcinoma patients in the Gizan Area of Saudi Arabia.沙特阿拉伯吉赞地区原发性肝细胞癌患者概况。
Cancer. 1986 Nov 1;58(9):2163-8. doi: 10.1002/1097-0142(19861101)58:9<2163::aid-cncr2820580934>3.0.co;2-2.
7
High prevalence of delta virus infection in Thai intravenous drug abusers.
Southeast Asian J Trop Med Public Health. 1988 Jun;19(2):191-5.
8
HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.丙型肝炎病毒相关肝细胞癌中的乙肝表面抗原阴性乙肝病毒感染
J Viral Hepat. 2005 May;12(3):325-9. doi: 10.1111/j.1365-2893.2005.00586.x.
9
Prevalence of delta antigen/antibody in various HBsAg positive patients in Saudi Arabia.沙特阿拉伯不同乙肝表面抗原(HBsAg)阳性患者中δ抗原/抗体的流行情况。
Prog Clin Biol Res. 1987;234:471-5.
10
Immunohistochemical research of HDV infection in Chinese patients with chronic liver disease.中国慢性肝病患者丁型肝炎病毒感染的免疫组织化学研究。
Hepatogastroenterology. 1990 Aug;37(4):411-2.

引用本文的文献

1
Prevalence and molecular characterization of hepatitis D virus in Saudi Arabia: A single-center study.沙特阿拉伯丁型肝炎病毒的流行情况及分子特征:一项单中心研究。
Saudi J Gastroenterol. 2017 May-Jun;23(3):176-182. doi: 10.4103/sjg.SJG_515_16.
2
The chemo-prophylactic efficacy of an ethanol Moringa oleifera leaf extract against hepatocellular carcinoma in rats.辣木树叶乙醇提取物对大鼠肝细胞癌的化学预防功效
Pharm Biol. 2017 Dec;55(1):1458-1466. doi: 10.1080/13880209.2017.1306713.
3
Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors.
经皮不可逆电穿孔:71 例无法手术切除的恶性肝肿瘤患者的长期生存分析。
Sci Rep. 2017 Mar 7;7:43687. doi: 10.1038/srep43687.
4
Protective Effect of Prosopis cineraria Against N-Nitrosodiethylamine Induced Liver Tumor by Modulating Membrane Bound Enzymes and Glycoproteins.灰叶豆对N-亚硝基二乙胺诱导的肝肿瘤的保护作用:通过调节膜结合酶和糖蛋白实现
Adv Pharm Bull. 2012;2(2):179-82. doi: 10.5681/apb.2012.027. Epub 2012 Jun 30.
5
Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis.东地中海地区丁型肝炎的患病率:系统评价与荟萃分析
Hepat Mon. 2013 Jan;13(1):e8210. doi: 10.5812/hepatmon.8210. Epub 2013 Jan 6.
6
Hepatitis D: Scenario in the Asia-Pacific region.肝炎 D:亚太地区情况。
World J Gastroenterol. 2010 Feb 7;16(5):554-62. doi: 10.3748/wjg.v16.i5.554.
7
Immunological treatment of liver tumors.肝脏肿瘤的免疫治疗
World J Gastroenterol. 2005 Nov 14;11(42):6571-6. doi: 10.3748/wjg.v11.i42.6571.
8
Therapeutic management algorithm in cirrhotic and noncirrhotic patients in primary or secondary liver masses.
Dig Dis Sci. 2004 May;49(5):866-71. doi: 10.1023/b:ddas.0000030101.81734.47.
9
Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients.不可切除的原发性和转移性肝恶性肿瘤的射频消融:123例患者的结果
Ann Surg. 1999 Jul;230(1):1-8. doi: 10.1097/00000658-199907000-00001.